Description
5-Amino-1MQ
100 mg
(also known as 5-amino-1-methylquinolinium or 5-amino-1-methylquinolin-2(1H)-one) is a synthetic small-molecule compound studied primarily as a selective inhibitor of the enzyme **nicotinamide N-methyltransferase (NNMT).
It is not a traditional peptide (despite sometimes being discussed in peptide therapy contexts) but a small, membrane-permeable molecule investigated in preclinical research for its effects on metabolism, fat storage, and cellular energy pathways. It is typically explored in research or wellness settings as an oral capsule or injectable, though it remains primarily a research compound rather than a widely approved therapeutic drug.
How It Works (Mechanism of Action)
NNMT is an enzyme that becomes more active with aging, obesity, and in certain tissues like fat (adipose) and muscle. It methylates nicotinamide (a breakdown product of **NAD+**, a critical coenzyme for energy production and cellular repair), which diverts nicotinamide away from the NAD+ salvage pathway. This leads to:
– Lower NAD+ levels
– Reduced mitochondrial efficiency
– Increased fat storage and larger fat cells (adipocytes)
– Slower metabolism and potential insulin resistance
By inhibiting NNMT, 5-Amino-1MQ helps:
– Preserve and elevate intracellular NAD+ levels
– Enhance mitochondrial function and energy production
– Promote fat oxidation (burning fat for fuel) while suppressing lipogenesis (fat creation)
– Potentially activate sirtuins (like SIRT1), proteins linked to longevity and metabolic health
– Shrink fat cell size and reduce visceral (deep abdominal) fat accumulation
This creates a shift toward better metabolic flexibility, where the body more efficiently uses stored fat without significantly affecting food intake in studies.
Potential Benefits (Based on Preclinical Research)
Most evidence comes from animal (mouse) studies and in vitro (cell) research, with limited human clinical data available as of 2026. Reported or suggested benefits include:
– Fat loss and body composition improvement** — Significant reductions in body weight, white adipose tissue mass, and fat cell size in diet-induced obese mice, sometimes normalizing levels to those of lean controls when combined with a lower-fat diet. It appears to target stubborn/visceral fat while helping preserve lean muscle mass during caloric deficits.
– Enhanced metabolism and energy levels** — By boosting NAD+ and mitochondrial output, it may increase basal metabolic rate, fat oxidation, and overall energy expenditure, potentially reducing fatigue.
– Improved insulin sensitivity and glucose handling** — Studies show potential to lower insulin resistance and support better blood sugar control, which could benefit metabolic health and type 2 diabetes-related pathways.
– Muscle preservation and performance support** — In aged or exercised mice, it has shown additive benefits with training for grip strength, running distance, and reduced muscle fat accumulation, suggesting it may help maintain muscle quality and recovery.
– Anti-aging and longevity potential** — Indirect NAD+ preservation and SIRT1 activation may support cellular repair, reduce inflammation in fat tissue, and combat age-related metabolic slowdown.
– Other exploratory effects** — Possible support for converting white fat to more metabolically active brown fat (thermogenesis), though this is less established.
These effects are often described as working “at the cellular level” rather than through appetite suppression (unlike GLP-1 drugs such as semaglutide). Some wellness clinics market it for weight management, energy optimization, and body recomposition, often stacked with NAD+ therapies or other compounds.
In summary, 5-Amino-1MQ is an NNMT inhibitor designed to “release the brakes” on metabolism by preserving NAD+ and optimizing how cells handle energy and fat. It shows promise for fat loss, metabolic health, and muscle support in research models, making it popular in longevity and performance circles.
